secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2026-07-15T20:10:42+00:00
Accession:  0001493152-26-033358
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra reports ATR-COSF ex vivo results: 4.4-fold elasticity increase, improved distribution
--------------------------------------------------------------------------------

- ATR-COSF supernatant with recombinant filaggrin showed increased penetration into stratum granulosum with multiple doses in ex vivo human skin.
- Hydrogel with 7.5% w/w supernatant increased skin elasticity 4.4-fold; 0.28% w/w restored elasticity to healthy skin levels.
- Safety testing confirmed 2% supernatant formulation is non-irritating and non-corrosive to skin and eyes.
- CEO plans to optimize formulations and initiate human study for visible wrinkle reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000149315226033358/0001493152-26-033358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000149315226033358/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-033358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer